Optimal dose of benzathine penicillin G for the treatment of early syphilis in HIV-infected patients in the era of combination antiretroviral therapy

Yang C.-J.Chen Y.-H.Tsai M.-S.CHIEN-CHING HUNG2021-12-012021-12-0120151058-4838https://www.scopus.com/inward/record.uri?eid=2-s2.0-84928896253&doi=10.1093%2fcid%2fciv029&partnerID=40&md5=bef6b7bf5d1cb546477088506bdb92dbhttps://scholars.lib.ntu.edu.tw/handle/123456789/588804[SDGs]SDG3antiretrovirus agent; benzathine penicillin; antitreponemal agent; benzathine penicillin; antibiotic therapy; cohort analysis; disease course; high risk population; human; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; Letter; major clinical study; multicenter study (topic); optimal drug dose; priority journal; prospective study; reinfection; repeated drug dose; serology; sexually transmitted disease; single drug dose; syphilis; treatment failure; treatment response; complication; female; Human immunodeficiency virus infection; male; syphilis; Antitreponemal Agents; Female; HIV Infections; Humans; Male; Penicillin G Benzathine; SyphilisOptimal dose of benzathine penicillin G for the treatment of early syphilis in HIV-infected patients in the era of combination antiretroviral therapyletter10.1093/cid/civ029256283832-s2.0-84928896253